XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Concentrations of Credit Risk and Current Expected Credit Losses (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Risks and Uncertainties [Abstract] |
Schedule of concentration of credit risk related to collaborative partners | In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:
| Percentage of Total Net Product Revenues for the Three Months Ended |  | Percentage of Total Net Product Revenues for the Nine Months Ended
| September 30, |  | September 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Customer A | 19 | % |  | 19 | % |  | 19 | % |  | 19 | %
Customer B | 10 | % |  | 11 | % |  | 11 | % |  | 12 | %
Customer C | 15 | % |  | 17 | % |  | 18 | % |  | 18 | %
Customer D | 5 | % |  | 9 | % |  | 5 | % |  | 10 | %
Customer E | 9 | % |  | 11 | % |  | 10 | % |  | 11 | %

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners. + References No definition available. + Details
Name: | incy_SchedulesOfConcentrationOfRiskByRiskFactorRelatedToCollaborativePartnersTableTextBlock
Namespace Prefix: | incy_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration